Comparing Factor Use and Bleed Rates in US Hemophilia A Patients Receiving Prophylaxis With 3 Different Long-Acting Recombinant Factor VIII Products
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Pembrolizumab Plus Enfortumab Vedotin for MIBC
2
Global CKD Burden Nearly Doubles Since 1990, Reaching 788 Million Adults Worldwide
3
Different Communication of HIV Risk Affects PrEP Interest
4
CAR T-Cell Therapies, Bispecific Antibodies Usher in New Era in R/R MCL
5
